ZLDPF Zealand Pharma A/S

Total number of shares and voting rights in Zealand Pharma as of December 31, 2025

Total number of shares and voting rights in Zealand Pharma as of December 31, 2025

Company announcement – No. 27 / 2025

Total number of shares and voting rights in Zealand Pharma as of December 31, 2025

Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred.

In Company Announcement No. 25 / 2025 dated December 11, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Following this announcement, the table below details the total number of shares and voting rights in Zealand Pharma as of December 31, 2025.



 



Date		Number of shares

(nominal value of DKK 1 each)		Share capital

(nominal value in DKK)		Number of voting rights
December 31, 202571,515,04571,515,04571,515,045

The Company's Articles of Association are available on the Company's website .

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at .

Contacts

Adam Lange (Investors)

Vice President, Investor Relations

Zealand Pharma

Neshat Ahmadi (Investors)

Investor Relations Manager

Zealand Pharma

Rachel James-Owens (Media)

Vice President, Corporate Communications & Media Relations

Zealand Pharma



EN
31/12/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Mathijs Geerts Danau
  • Wim Lewi
ZLDPF ZEALAND PHARMA A/S
SHUR SHURGARD SELF STORAGE LIMITED
5h / 44m 5h / 44m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Enters agreement with DCAI to use AI supercomputer for ...

Zealand announced that it entered into an agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support its Metabolic Frontier 2030 strategy, to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030.The platform supports advanced characterization, simulation, and generative AI modelling for drug discovery and design. Financial terms were not disclosed. DKK 1,120 TP and BUY maintained.

ZLDPF ZEALAND PHARMA A/S
5h / 52m 5h / 52m 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomput...

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy ...

6h / 38m 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma to present at the J.P. Morgan Healthcare Conference

Zealand Pharma to present at the J.P. Morgan Healthcare Conference Press release – No. 1 / 2026 Zealand Pharma to present at the J.P. Morgan Healthcare Conference Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California. Adam Steensberg, President and Chief Executive Officer, will take part in a presenta...

January 5, 2026 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Total number of shares and voting rights in Zealand Pharma as of Decem...

Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Company announcement – No. 27 / 2025 Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which change...

December 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch